基本信息
views: 2
Career Trajectory
Bio
Epilepsy is a diverse collection of neurological disorders characterized by abnormal electrical activity in the brain leading to seizures. An estimated 50 million people worldwide are affected by some form of epilepsy, and startlingly, 30% of affected individuals are resistant to conventional treatments. We are investigating the detailed mechanism of action of a new class of anti-epileptic drug. Retigabine is the prototypical member of this class, and over the past few years has been approved for use in humans in Europe and North America. Retigabine has a unique mechanism of action: it is the only anti-epileptic drug that activates voltage-gated K+ channels in the brain. We investigate the molecular target of retigabine (KCNQ channels, or ‘M’-channels), and other drugs that are thought to target the voltage-sensing domain of these channels. We hope this work will accelerate the development of new anti-epileptic drugs, and develop our understanding of how mutations in these channels are linked to seizure disorders.
Research Interests
Papers共 113 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
biorxiv(2024)
CHANNELSno. 1 (2024)
BIOPHYSICAL JOURNALno. 3 (2023): 386A-386A
Biophysical journal (2023)
Functionno. 4 (2023)
Load More
Author Statistics
#Papers: 113
#Citation: 2168
H-Index: 25
G-Index: 44
Sociability: 6
Diversity: 3
Activity: 19
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn